Global Nifedipine Market

Nifedipine Comprehensive Study by Type (Initial dose(30 to 60 mg orally once a day), Maintenance dose (30 to 90 mg orally once a day), Maximum dose (Up to 120 mg/day)), Application (Heart Failure, Raynauds Syndrome, Cephalalgia, Bronchial Asthma, Hypertension, Angina Pectoris Prophylaxis, Angina Pectoris, Primary Pulmonary Hypertension), Availability of dose (10mg, 20mg, 30mg, 60mg, 90mg), Drug Delivery (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets) Players and Region - Global Market Outlook to 2024

Nifedipine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Nifedipine Market Overview:
Nifedipine belongs to a calcium channel blocker that comes under the dihydropyridine subclass. Primary uses of nifedipine are anti-hypertensive and anti-anginal medications. It relaxes the muscles of heart and blood vessels Nifedipine is used to treat hypertension (high blood pressure) and angina (chest pain). Nifedipine tablets come in an extended-release form and sustained released form of the drug. Nifedipine is also available in immediate-release oral capsules. They are also available in a generic drug. Nifedipine is used to lower blood pressure in people with hypertension, also used as part of combination therapy. Some of the key players profiled in the study are Pfizer (United States), Bayer (Germany), Actavis (United States), Teva (Israel), Shyndec (China), Honglin Pharma (China), Qingdao Huanghai Pharmaceutical (China), Yabao (China), Global Pharm (United States) and Huazhong Pharmaceutical Co Ltd (China).

On the basis of geography, the market of Nifedipine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Availability of dose, the sub-segment i.e. 10mg will boost the Nifedipine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Delivery, the sub-segment i.e. Nifedipine Controlled-Release Tablets will boost the Nifedipine market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing No Of Hypertension Patient
  • Rising Use In Combination Therapy

Market Trend
  • Used As A Second Line Of Treatment In Vasospastic Angina

Restraints
  • Problems Like Edema, Allergic Reaction, Low Blood Pressure Or Low Heart Rate, And Liver Damage Found
  • Drug-Drug Reactions Occur With The Following Categories That is Antibiotics, Antifungal Drugs, Antifungal Drugs, Antiviral Drugs
  • Lower Shelf Life

Opportunities
  • Availability In Generic Dose Also
  • Growing Government Support

Challenges
  • Short-Acting Nifedipine Is No Longer Considered Appropriate
  • Damages The Blood Vessels Of The Brain


Major Market Developments:

In August 2019 Bayer acquires BlueRock Therapeutics to build a leading position in cell therapy. Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology, and immunology.
In January 2020 granted approval for Bayer application for nifurtimox to treat pediatric patients with Chagas.A new formulation for the weight-adjusted treatment of pediatric Chagas patients age 0-18 targets most vulnerable patient group / Submission based on results of CHICO phase III clinical study of nifurtimox in pediatric patients with Chagas disease as well as pre-clinical data / Fight against Neglected Tropical Diseases part of Bayer’s Sustainability Strategy.
FDA approved following indication for nifedipine , that is Chronic stable angina, Vasospastic angina, and Hypertension. While in April 2019 FDA approved 30mg, 60mg, 90mg strengths tablets.
Increasing no of hypertension patients due to different reasons. The manufacturing companies have strong competition to earn the profit. Top companies, therefore, acquiring small firms to increase the overall business of the company. While mergers are another option to be in the market and catch the profit margins.

Target Audience:
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Industry Associate and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Nifedipine market on the basis of product [Initial dose(30 to 60 mg orally once a day), Maintenance dose (30 to 90 mg orally once a day) and Maximum dose (Up to 120 mg/day)] , application [Heart Failure, Raynauds Syndrome, Cephalalgia, Bronchial Asthma, Hypertension, Angina Pectoris Prophylaxis, Angina Pectoris and Primary Pulmonary Hypertension], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Nifedipine market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Nifedipine industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Vendors which are also part of the research are DEAFARMA (Italy), Moehs Group (Spain) and Qualitek pharma (India).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Nifedipine market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • Initial dose(30 to 60 mg orally once a day)
  • Maintenance dose (30 to 90 mg orally once a day)
  • Maximum dose (Up to 120 mg/day)
By Application
  • Heart Failure
  • Raynauds Syndrome
  • Cephalalgia
  • Bronchial Asthma
  • Hypertension
  • Angina Pectoris Prophylaxis
  • Angina Pectoris
  • Primary Pulmonary Hypertension
By Availability of dose
  • 10mg
  • 20mg
  • 30mg
  • 60mg
  • 90mg

By Drug Delivery
  • Nifedipine Controlled-Release Tablets
  • Nifedipine Extended Action Tablets

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing No Of Hypertension Patient
      • 3.2.2. Rising Use In Combination Therapy
    • 3.3. Market Challenges
      • 3.3.1. Short-Acting Nifedipine Is No Longer Considered Appropriate
      • 3.3.2. Damages The Blood Vessels Of The Brain
    • 3.4. Market Trends
      • 3.4.1. Used As A Second Line Of Treatment In Vasospastic Angina
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nifedipine, by Type, Application, Availability of dose, Drug Delivery and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Nifedipine (Value)
      • 5.2.1. Global Nifedipine by: Type (Value)
        • 5.2.1.1. Initial dose(30 to 60 mg orally once a day)
        • 5.2.1.2. Maintenance dose (30 to 90 mg orally once a day)
        • 5.2.1.3. Maximum dose (Up to 120 mg/day)
      • 5.2.2. Global Nifedipine by: Application (Value)
        • 5.2.2.1. Heart Failure
        • 5.2.2.2. Raynauds Syndrome
        • 5.2.2.3. Cephalalgia
        • 5.2.2.4. Bronchial Asthma
        • 5.2.2.5. Hypertension
        • 5.2.2.6. Angina Pectoris Prophylaxis
        • 5.2.2.7. Angina Pectoris
        • 5.2.2.8. Primary Pulmonary Hypertension
      • 5.2.3. Global Nifedipine by: Availability of dose (Value)
        • 5.2.3.1. 10mg
        • 5.2.3.2. 20mg
        • 5.2.3.3. 30mg
        • 5.2.3.4. 60mg
        • 5.2.3.5. 90mg
      • 5.2.4. Global Nifedipine by: Drug Delivery (Value)
        • 5.2.4.1. Nifedipine Controlled-Release Tablets
        • 5.2.4.2. Nifedipine Extended Action Tablets
      • 5.2.5. Global Nifedipine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Nifedipine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Actavis (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Shyndec (China)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Honglin Pharma (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Qingdao Huanghai Pharmaceutical (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Yabao (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Global Pharm (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Huazhong Pharmaceutical Co Ltd (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nifedipine Sale, by Type, Application, Availability of dose, Drug Delivery and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Nifedipine (Value)
      • 7.2.1. Global Nifedipine by: Type (Value)
        • 7.2.1.1. Initial dose(30 to 60 mg orally once a day)
        • 7.2.1.2. Maintenance dose (30 to 90 mg orally once a day)
        • 7.2.1.3. Maximum dose (Up to 120 mg/day)
      • 7.2.2. Global Nifedipine by: Application (Value)
        • 7.2.2.1. Heart Failure
        • 7.2.2.2. Raynauds Syndrome
        • 7.2.2.3. Cephalalgia
        • 7.2.2.4. Bronchial Asthma
        • 7.2.2.5. Hypertension
        • 7.2.2.6. Angina Pectoris Prophylaxis
        • 7.2.2.7. Angina Pectoris
        • 7.2.2.8. Primary Pulmonary Hypertension
      • 7.2.3. Global Nifedipine by: Availability of dose (Value)
        • 7.2.3.1. 10mg
        • 7.2.3.2. 20mg
        • 7.2.3.3. 30mg
        • 7.2.3.4. 60mg
        • 7.2.3.5. 90mg
      • 7.2.4. Global Nifedipine by: Drug Delivery (Value)
        • 7.2.4.1. Nifedipine Controlled-Release Tablets
        • 7.2.4.2. Nifedipine Extended Action Tablets
      • 7.2.5. Global Nifedipine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nifedipine: by Type(USD Million)
  • Table 2. Nifedipine Initial dose(30 to 60 mg orally once a day) , by Region USD Million (2013-2018)
  • Table 3. Nifedipine Maintenance dose (30 to 90 mg orally once a day) , by Region USD Million (2013-2018)
  • Table 4. Nifedipine Maximum dose (Up to 120 mg/day) , by Region USD Million (2013-2018)
  • Table 5. Nifedipine: by Application(USD Million)
  • Table 6. Nifedipine Heart Failure , by Region USD Million (2013-2018)
  • Table 7. Nifedipine Raynauds Syndrome , by Region USD Million (2013-2018)
  • Table 8. Nifedipine Cephalalgia , by Region USD Million (2013-2018)
  • Table 9. Nifedipine Bronchial Asthma , by Region USD Million (2013-2018)
  • Table 10. Nifedipine Hypertension , by Region USD Million (2013-2018)
  • Table 11. Nifedipine Angina Pectoris Prophylaxis , by Region USD Million (2013-2018)
  • Table 12. Nifedipine Angina Pectoris , by Region USD Million (2013-2018)
  • Table 13. Nifedipine Primary Pulmonary Hypertension , by Region USD Million (2013-2018)
  • Table 14. Nifedipine: by Availability of dose(USD Million)
  • Table 15. Nifedipine 10mg , by Region USD Million (2013-2018)
  • Table 16. Nifedipine 20mg , by Region USD Million (2013-2018)
  • Table 17. Nifedipine 30mg , by Region USD Million (2013-2018)
  • Table 18. Nifedipine 60mg , by Region USD Million (2013-2018)
  • Table 19. Nifedipine 90mg , by Region USD Million (2013-2018)
  • Table 20. Nifedipine: by Drug Delivery(USD Million)
  • Table 21. Nifedipine Nifedipine Controlled-Release Tablets , by Region USD Million (2013-2018)
  • Table 22. Nifedipine Nifedipine Extended Action Tablets , by Region USD Million (2013-2018)
  • Table 23. South America Nifedipine, by Country USD Million (2013-2018)
  • Table 24. South America Nifedipine, by Type USD Million (2013-2018)
  • Table 25. South America Nifedipine, by Application USD Million (2013-2018)
  • Table 26. South America Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 27. South America Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 28. Brazil Nifedipine, by Type USD Million (2013-2018)
  • Table 29. Brazil Nifedipine, by Application USD Million (2013-2018)
  • Table 30. Brazil Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 31. Brazil Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 32. Argentina Nifedipine, by Type USD Million (2013-2018)
  • Table 33. Argentina Nifedipine, by Application USD Million (2013-2018)
  • Table 34. Argentina Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 35. Argentina Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 36. Rest of South America Nifedipine, by Type USD Million (2013-2018)
  • Table 37. Rest of South America Nifedipine, by Application USD Million (2013-2018)
  • Table 38. Rest of South America Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 39. Rest of South America Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 40. Asia Pacific Nifedipine, by Country USD Million (2013-2018)
  • Table 41. Asia Pacific Nifedipine, by Type USD Million (2013-2018)
  • Table 42. Asia Pacific Nifedipine, by Application USD Million (2013-2018)
  • Table 43. Asia Pacific Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 44. Asia Pacific Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 45. China Nifedipine, by Type USD Million (2013-2018)
  • Table 46. China Nifedipine, by Application USD Million (2013-2018)
  • Table 47. China Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 48. China Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 49. Japan Nifedipine, by Type USD Million (2013-2018)
  • Table 50. Japan Nifedipine, by Application USD Million (2013-2018)
  • Table 51. Japan Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 52. Japan Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 53. India Nifedipine, by Type USD Million (2013-2018)
  • Table 54. India Nifedipine, by Application USD Million (2013-2018)
  • Table 55. India Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 56. India Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 57. South Korea Nifedipine, by Type USD Million (2013-2018)
  • Table 58. South Korea Nifedipine, by Application USD Million (2013-2018)
  • Table 59. South Korea Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 60. South Korea Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 61. Taiwan Nifedipine, by Type USD Million (2013-2018)
  • Table 62. Taiwan Nifedipine, by Application USD Million (2013-2018)
  • Table 63. Taiwan Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 64. Taiwan Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 65. Australia Nifedipine, by Type USD Million (2013-2018)
  • Table 66. Australia Nifedipine, by Application USD Million (2013-2018)
  • Table 67. Australia Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 68. Australia Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 69. Rest of Asia-Pacific Nifedipine, by Type USD Million (2013-2018)
  • Table 70. Rest of Asia-Pacific Nifedipine, by Application USD Million (2013-2018)
  • Table 71. Rest of Asia-Pacific Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 72. Rest of Asia-Pacific Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 73. Europe Nifedipine, by Country USD Million (2013-2018)
  • Table 74. Europe Nifedipine, by Type USD Million (2013-2018)
  • Table 75. Europe Nifedipine, by Application USD Million (2013-2018)
  • Table 76. Europe Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 77. Europe Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 78. Germany Nifedipine, by Type USD Million (2013-2018)
  • Table 79. Germany Nifedipine, by Application USD Million (2013-2018)
  • Table 80. Germany Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 81. Germany Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 82. France Nifedipine, by Type USD Million (2013-2018)
  • Table 83. France Nifedipine, by Application USD Million (2013-2018)
  • Table 84. France Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 85. France Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 86. Italy Nifedipine, by Type USD Million (2013-2018)
  • Table 87. Italy Nifedipine, by Application USD Million (2013-2018)
  • Table 88. Italy Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 89. Italy Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 90. United Kingdom Nifedipine, by Type USD Million (2013-2018)
  • Table 91. United Kingdom Nifedipine, by Application USD Million (2013-2018)
  • Table 92. United Kingdom Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 93. United Kingdom Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 94. Netherlands Nifedipine, by Type USD Million (2013-2018)
  • Table 95. Netherlands Nifedipine, by Application USD Million (2013-2018)
  • Table 96. Netherlands Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 97. Netherlands Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 98. Rest of Europe Nifedipine, by Type USD Million (2013-2018)
  • Table 99. Rest of Europe Nifedipine, by Application USD Million (2013-2018)
  • Table 100. Rest of Europe Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 101. Rest of Europe Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 102. MEA Nifedipine, by Country USD Million (2013-2018)
  • Table 103. MEA Nifedipine, by Type USD Million (2013-2018)
  • Table 104. MEA Nifedipine, by Application USD Million (2013-2018)
  • Table 105. MEA Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 106. MEA Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 107. Middle East Nifedipine, by Type USD Million (2013-2018)
  • Table 108. Middle East Nifedipine, by Application USD Million (2013-2018)
  • Table 109. Middle East Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 110. Middle East Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 111. Africa Nifedipine, by Type USD Million (2013-2018)
  • Table 112. Africa Nifedipine, by Application USD Million (2013-2018)
  • Table 113. Africa Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 114. Africa Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 115. North America Nifedipine, by Country USD Million (2013-2018)
  • Table 116. North America Nifedipine, by Type USD Million (2013-2018)
  • Table 117. North America Nifedipine, by Application USD Million (2013-2018)
  • Table 118. North America Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 119. North America Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 120. United States Nifedipine, by Type USD Million (2013-2018)
  • Table 121. United States Nifedipine, by Application USD Million (2013-2018)
  • Table 122. United States Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 123. United States Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 124. Canada Nifedipine, by Type USD Million (2013-2018)
  • Table 125. Canada Nifedipine, by Application USD Million (2013-2018)
  • Table 126. Canada Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 127. Canada Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 128. Mexico Nifedipine, by Type USD Million (2013-2018)
  • Table 129. Mexico Nifedipine, by Application USD Million (2013-2018)
  • Table 130. Mexico Nifedipine, by Availability of dose USD Million (2013-2018)
  • Table 131. Mexico Nifedipine, by Drug Delivery USD Million (2013-2018)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Nifedipine: by Type(USD Million)
  • Table 143. Nifedipine Initial dose(30 to 60 mg orally once a day) , by Region USD Million (2019-2024)
  • Table 144. Nifedipine Maintenance dose (30 to 90 mg orally once a day) , by Region USD Million (2019-2024)
  • Table 145. Nifedipine Maximum dose (Up to 120 mg/day) , by Region USD Million (2019-2024)
  • Table 146. Nifedipine: by Application(USD Million)
  • Table 147. Nifedipine Heart Failure , by Region USD Million (2019-2024)
  • Table 148. Nifedipine Raynauds Syndrome , by Region USD Million (2019-2024)
  • Table 149. Nifedipine Cephalalgia , by Region USD Million (2019-2024)
  • Table 150. Nifedipine Bronchial Asthma , by Region USD Million (2019-2024)
  • Table 151. Nifedipine Hypertension , by Region USD Million (2019-2024)
  • Table 152. Nifedipine Angina Pectoris Prophylaxis , by Region USD Million (2019-2024)
  • Table 153. Nifedipine Angina Pectoris , by Region USD Million (2019-2024)
  • Table 154. Nifedipine Primary Pulmonary Hypertension , by Region USD Million (2019-2024)
  • Table 155. Nifedipine: by Availability of dose(USD Million)
  • Table 156. Nifedipine 10mg , by Region USD Million (2019-2024)
  • Table 157. Nifedipine 20mg , by Region USD Million (2019-2024)
  • Table 158. Nifedipine 30mg , by Region USD Million (2019-2024)
  • Table 159. Nifedipine 60mg , by Region USD Million (2019-2024)
  • Table 160. Nifedipine 90mg , by Region USD Million (2019-2024)
  • Table 161. Nifedipine: by Drug Delivery(USD Million)
  • Table 162. Nifedipine Nifedipine Controlled-Release Tablets , by Region USD Million (2019-2024)
  • Table 163. Nifedipine Nifedipine Extended Action Tablets , by Region USD Million (2019-2024)
  • Table 164. South America Nifedipine, by Country USD Million (2019-2024)
  • Table 165. South America Nifedipine, by Type USD Million (2019-2024)
  • Table 166. South America Nifedipine, by Application USD Million (2019-2024)
  • Table 167. South America Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 168. South America Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 169. Brazil Nifedipine, by Type USD Million (2019-2024)
  • Table 170. Brazil Nifedipine, by Application USD Million (2019-2024)
  • Table 171. Brazil Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 172. Brazil Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 173. Argentina Nifedipine, by Type USD Million (2019-2024)
  • Table 174. Argentina Nifedipine, by Application USD Million (2019-2024)
  • Table 175. Argentina Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 176. Argentina Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 177. Rest of South America Nifedipine, by Type USD Million (2019-2024)
  • Table 178. Rest of South America Nifedipine, by Application USD Million (2019-2024)
  • Table 179. Rest of South America Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 180. Rest of South America Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 181. Asia Pacific Nifedipine, by Country USD Million (2019-2024)
  • Table 182. Asia Pacific Nifedipine, by Type USD Million (2019-2024)
  • Table 183. Asia Pacific Nifedipine, by Application USD Million (2019-2024)
  • Table 184. Asia Pacific Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 185. Asia Pacific Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 186. China Nifedipine, by Type USD Million (2019-2024)
  • Table 187. China Nifedipine, by Application USD Million (2019-2024)
  • Table 188. China Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 189. China Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 190. Japan Nifedipine, by Type USD Million (2019-2024)
  • Table 191. Japan Nifedipine, by Application USD Million (2019-2024)
  • Table 192. Japan Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 193. Japan Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 194. India Nifedipine, by Type USD Million (2019-2024)
  • Table 195. India Nifedipine, by Application USD Million (2019-2024)
  • Table 196. India Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 197. India Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 198. South Korea Nifedipine, by Type USD Million (2019-2024)
  • Table 199. South Korea Nifedipine, by Application USD Million (2019-2024)
  • Table 200. South Korea Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 201. South Korea Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 202. Taiwan Nifedipine, by Type USD Million (2019-2024)
  • Table 203. Taiwan Nifedipine, by Application USD Million (2019-2024)
  • Table 204. Taiwan Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 205. Taiwan Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 206. Australia Nifedipine, by Type USD Million (2019-2024)
  • Table 207. Australia Nifedipine, by Application USD Million (2019-2024)
  • Table 208. Australia Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 209. Australia Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 210. Rest of Asia-Pacific Nifedipine, by Type USD Million (2019-2024)
  • Table 211. Rest of Asia-Pacific Nifedipine, by Application USD Million (2019-2024)
  • Table 212. Rest of Asia-Pacific Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 213. Rest of Asia-Pacific Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 214. Europe Nifedipine, by Country USD Million (2019-2024)
  • Table 215. Europe Nifedipine, by Type USD Million (2019-2024)
  • Table 216. Europe Nifedipine, by Application USD Million (2019-2024)
  • Table 217. Europe Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 218. Europe Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 219. Germany Nifedipine, by Type USD Million (2019-2024)
  • Table 220. Germany Nifedipine, by Application USD Million (2019-2024)
  • Table 221. Germany Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 222. Germany Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 223. France Nifedipine, by Type USD Million (2019-2024)
  • Table 224. France Nifedipine, by Application USD Million (2019-2024)
  • Table 225. France Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 226. France Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 227. Italy Nifedipine, by Type USD Million (2019-2024)
  • Table 228. Italy Nifedipine, by Application USD Million (2019-2024)
  • Table 229. Italy Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 230. Italy Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 231. United Kingdom Nifedipine, by Type USD Million (2019-2024)
  • Table 232. United Kingdom Nifedipine, by Application USD Million (2019-2024)
  • Table 233. United Kingdom Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 234. United Kingdom Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 235. Netherlands Nifedipine, by Type USD Million (2019-2024)
  • Table 236. Netherlands Nifedipine, by Application USD Million (2019-2024)
  • Table 237. Netherlands Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 238. Netherlands Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 239. Rest of Europe Nifedipine, by Type USD Million (2019-2024)
  • Table 240. Rest of Europe Nifedipine, by Application USD Million (2019-2024)
  • Table 241. Rest of Europe Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 242. Rest of Europe Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 243. MEA Nifedipine, by Country USD Million (2019-2024)
  • Table 244. MEA Nifedipine, by Type USD Million (2019-2024)
  • Table 245. MEA Nifedipine, by Application USD Million (2019-2024)
  • Table 246. MEA Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 247. MEA Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 248. Middle East Nifedipine, by Type USD Million (2019-2024)
  • Table 249. Middle East Nifedipine, by Application USD Million (2019-2024)
  • Table 250. Middle East Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 251. Middle East Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 252. Africa Nifedipine, by Type USD Million (2019-2024)
  • Table 253. Africa Nifedipine, by Application USD Million (2019-2024)
  • Table 254. Africa Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 255. Africa Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 256. North America Nifedipine, by Country USD Million (2019-2024)
  • Table 257. North America Nifedipine, by Type USD Million (2019-2024)
  • Table 258. North America Nifedipine, by Application USD Million (2019-2024)
  • Table 259. North America Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 260. North America Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 261. United States Nifedipine, by Type USD Million (2019-2024)
  • Table 262. United States Nifedipine, by Application USD Million (2019-2024)
  • Table 263. United States Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 264. United States Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 265. Canada Nifedipine, by Type USD Million (2019-2024)
  • Table 266. Canada Nifedipine, by Application USD Million (2019-2024)
  • Table 267. Canada Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 268. Canada Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 269. Mexico Nifedipine, by Type USD Million (2019-2024)
  • Table 270. Mexico Nifedipine, by Application USD Million (2019-2024)
  • Table 271. Mexico Nifedipine, by Availability of dose USD Million (2019-2024)
  • Table 272. Mexico Nifedipine, by Drug Delivery USD Million (2019-2024)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nifedipine: by Type USD Million (2013-2018)
  • Figure 5. Global Nifedipine: by Application USD Million (2013-2018)
  • Figure 6. Global Nifedipine: by Availability of dose USD Million (2013-2018)
  • Figure 7. Global Nifedipine: by Drug Delivery USD Million (2013-2018)
  • Figure 8. South America Nifedipine Share (%), by Country
  • Figure 9. Asia Pacific Nifedipine Share (%), by Country
  • Figure 10. Europe Nifedipine Share (%), by Country
  • Figure 11. MEA Nifedipine Share (%), by Country
  • Figure 12. North America Nifedipine Share (%), by Country
  • Figure 13. Global Nifedipine share by Players 2018 (%)
  • Figure 14. Global Nifedipine share by Players (Top 3) 2018(%)
  • Figure 15. Global Nifedipine share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer (United States) Revenue: by Geography 2018
  • Figure 19. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer (Germany) Revenue: by Geography 2018
  • Figure 21. Actavis (United States) Revenue, Net Income and Gross profit
  • Figure 22. Actavis (United States) Revenue: by Geography 2018
  • Figure 23. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Teva (Israel) Revenue: by Geography 2018
  • Figure 25. Shyndec (China) Revenue, Net Income and Gross profit
  • Figure 26. Shyndec (China) Revenue: by Geography 2018
  • Figure 27. Honglin Pharma (China) Revenue, Net Income and Gross profit
  • Figure 28. Honglin Pharma (China) Revenue: by Geography 2018
  • Figure 29. Qingdao Huanghai Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 30. Qingdao Huanghai Pharmaceutical (China) Revenue: by Geography 2018
  • Figure 31. Yabao (China) Revenue, Net Income and Gross profit
  • Figure 32. Yabao (China) Revenue: by Geography 2018
  • Figure 33. Global Pharm (United States) Revenue, Net Income and Gross profit
  • Figure 34. Global Pharm (United States) Revenue: by Geography 2018
  • Figure 35. Huazhong Pharmaceutical Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 36. Huazhong Pharmaceutical Co Ltd (China) Revenue: by Geography 2018
  • Figure 37. Global Nifedipine: by Type USD Million (2019-2024)
  • Figure 38. Global Nifedipine: by Application USD Million (2019-2024)
  • Figure 39. Global Nifedipine: by Availability of dose USD Million (2019-2024)
  • Figure 40. Global Nifedipine: by Drug Delivery USD Million (2019-2024)
  • Figure 41. South America Nifedipine Share (%), by Country
  • Figure 42. Asia Pacific Nifedipine Share (%), by Country
  • Figure 43. Europe Nifedipine Share (%), by Country
  • Figure 44. MEA Nifedipine Share (%), by Country
  • Figure 45. North America Nifedipine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Bayer (Germany)
  • Actavis (United States)
  • Teva (Israel)
  • Shyndec (China)
  • Honglin Pharma (China)
  • Qingdao Huanghai Pharmaceutical (China)
  • Yabao (China)
  • Global Pharm (United States)
  • Huazhong Pharmaceutical Co Ltd (China)
Additional players considered in the study are as follows:
DEAFARMA (Italy) , Moehs Group (Spain) , Qualitek pharma (India)
Select User Access Type

Key Highlights of Report


Feb 2020 202 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nifedipine Market Quantitative research analysis
Global Nifedipine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Nifedipine Market Report?

Have a Query? Click Here

Other Related Reports

Resorcinol Comprehensive Study by Application (Tire and Rubber Products, Wood Adhesives and Binders, UV Products and Dyes, Flame Retardants, Others), Distribution Channel (Direct, Indirect), Producti...
$ 3750
Biodegradable Polyester Comprehensive Study by Type (Polylactic Acid (PLA), Polyglycolic Acid (PGA), Poly-Ε-Caprolactone (PCL), Polyhydroxybutyrate (PHB), Poly(3-Hydroxy Valerate), Others), Appl...
$ 3750
Ammonium Bicarbonate Comprehensive Study by Type (Agriculture Grade, Food Grade, Technical Grade), Application (Solvent, Raising agent, Nitrogen Fertilizer, Others), End Use (Food Industry, Agricultu...
$ 3650
Glass Bonding Adhesives Comprehensive Study by Type (Two-Component Adhesives, UV Adhesives), Application (Furniture, Mirrors, Glassware, Art Glass, Lampshades, Others), Industry Verticals (Furniture ...
$ 3650
Ferric Chloride Comprehensive Study by Type (Medication, Therapy, Surgery), Application (Catalyst, Etching Agent, Wastewater Treatment, Laboratory, Pet Care, Others), Form (Liquid, Powder), Sales Cha...
$ 3350
D-Mannose Comprehensive Study by Type (Food Grade, Pharmaceutical Grade), Application (Dietary Supplement, Food Additives, Anti-Inflammatory Agent, Others), Form (Capsule, Powder, Tablet), Sales Chan...
$ 3450